本刊从这一期起设立《新药情报》栏目,旨在为读者提供新药情报信息什么是新药?根据我国卫生部颁布的新药审批办法的规定,新药系指我国末生产过的药品。国外已批准生产并已列入一国药典的原料药品及其制剂为第四类新药,未列入一国药典者为二类新药。本栏暂以这类新药为选题对象。每期选择若干疗效确切并为国内临床需求的新药,采用文献汇编的形式,介绍它们的合成、制备、性状、质量分析、构效关系、临床前药理(药效、药代动力学与毒性)、临床药理与临床使用方面的综述或原著的文献出处,为 This issue from this issue since the establishment of “new drug information” section, aimed at providing readers with new drug information What is a new drug? According to China’s Ministry of Health promulgated the new drug approval measures, the new drug refers to the end of China’s production of drugs. Foreign countries have approved the production and has been included in the Pharmacopoeia of a country’s raw materials drugs and their preparations for the fourth category of new drugs, not included in a country Pharmacopoeia as two types of new drugs. This column temporarily to this new drug for the title of the object. Each issue selects a number of new drugs that have a definite therapeutic effect and are clinically required for clinical use in the form of a compilation of documents describing their synthesis, preparation, traits, quality analysis, structure-activity relationship, preclinical pharmacology (pharmacodynamics, pharmacokinetics and toxicity) , Clinical pharmacology and clinical use of the review or the original source of the literature